secwatch.observer — SEC 8-K summary
======================================

Issuer:     MeiraGTx Holdings plc (MGTX)
CIK:        0001735438
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001104659-26-034904
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.02, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MeiraGTx: FDA Breakthrough for xerostomia, FY2025 net loss $114.2M, $200M Hologen JV
--------------------------------------------------------------------------------

- FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for radiation-induced xerostomia; RMAT also granted.
- Strategic JV with Hologen: $200M upfront, $230M additional funding for AAV-GAD, MeiraGTx holds 30% ownership.
- Collaboration with Lilly: $75M upfront, >$400M milestones for AAV-AIPL1 and other ocular assets.
- FY2025 net loss $114.2M ($1.42/share) vs $147.8M ($2.12/share) in FY2024; cash $68.2M.
- Debt amendment: maturity extended to May 2027, $25M redemption by June 30, 2026, warrant price reduced to $8.00.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1735438/000110465926034904/0001104659-26-034904-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1735438/000110465926034904/mgtx-20260325x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-034904

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer